Personalized medicine

Predictive Oncology Reports 2019 Full-year Financial Results

Wednesday, April 1, 2020 - 1:45pm

MINNEAPOLIS, April 01, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (Predictive Oncology or the Company), a knowledge-driven company focused on applying artificial intelligence (AI) to personalized medicine and drug discovery, today reported financial results for its full year ended December 31, 2019, as well as select corporate highlights.

Key Points: 
  • MINNEAPOLIS, April 01, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (Predictive Oncology or the Company), a knowledge-driven company focused on applying artificial intelligence (AI) to personalized medicine and drug discovery, today reported financial results for its full year ended December 31, 2019, as well as select corporate highlights.
  • Against this backdrop, we believe that Predictive Oncology will continue to be a pioneer within the fields of biomarker discovery and precision therapies going forward.
  • In addition, Predictive Oncology recognized a credit loss of $1.0 million in notes receivable from CytoBioscience (now operating as InventaBioTech).
  • Predictive Oncology (Nasdaq: POAI) operates through three segments (Domestic, International and Helomics), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe.

POAI Subsidiary Helomics Continues Progress Towards Goal of Developing an AI-Driven Predictive Model of Ovarian Cancer

Tuesday, March 31, 2020 - 1:30pm

MINNEAPOLIS, March 31, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI ) (POAI or the Company), a knowledge-driven company focused on applying artificial intelligence (AI) to personalized medicine and drug discovery, today announced continued progress towards by its Helomics subsidiary towards the goal of developing an AI-driven predictive model of ovarian cancer (CancerQuest 2020).

Key Points: 
  • MINNEAPOLIS, March 31, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI ) (POAI or the Company), a knowledge-driven company focused on applying artificial intelligence (AI) to personalized medicine and drug discovery, today announced continued progress towards by its Helomics subsidiary towards the goal of developing an AI-driven predictive model of ovarian cancer (CancerQuest 2020).
  • CancerQuest2020 ( CCQ2020 ) is focused on building an AI-driven model of ovarian cancer that will predict drug response and outcome.
  • POAI is bringingprecision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer.
  • Predictive Oncology (Nasdaq: POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe.

Global Companion Diagnostics Market to 2026 - Opportunity Analysis for New Entrants - ResearchAndMarkets.com

Monday, March 30, 2020 - 10:51am

The "Global Companion Diagnostics Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Companion Diagnostics Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.
  • The Global Companion Diagnostics market is expected to reach $11.12 billion by 2026 growing at a CAGR of 17.7% from 2018 to 2026.
  • A companion diagnostic is an in vitro medicinal device that provides data which is fundamental for the safe and effective utilization of a corresponding drug or biological product.
  • Some of the factors such as increasing importance of personalized medicine and rising global incidence of cancer are fuelling the market growth.

Aquavit Pharmaceuticals, Inc. Announces Filing of New Patent Applications for a New Drug Delivery Platform and Vaccine Compositions for Immunizing Patients Against COVID-19 Caused by the SARS-CoV-2 Coronavirus

Friday, March 27, 2020 - 2:37pm

The patent applications cover platform technologies directed to novel methods for immunizing patients against infectious diseases such as COVID-19 using microchannel delivery devices.

Key Points: 
  • The patent applications cover platform technologies directed to novel methods for immunizing patients against infectious diseases such as COVID-19 using microchannel delivery devices.
  • Aquavit's microchannel technology overcomes the existing problems of vaccine delivery while also avoiding bleeding and pain that are normally associated with commercially available immunization methods.
  • Aquavit Pharmaceuticals, Inc., located in New York City, is developing several innovative products and platform technology IP for personalized medicine.
  • The company's mission is to modernize and personalize healthcare for patients through innovative drug and biologics delivery systems.

Vyripharm Biopharmaceuticals Is in the Development Stage of a Novel Integrated Theranostic Approach for the Treatment of Viral Infections Such as COVID-19

Friday, March 27, 2020 - 3:40am

This theranostic approach will use radiopharmaceuticals for detection and diagnosis with the ability to incorporate combination therapies to interrupt the replication of the virus.

Key Points: 
  • This theranostic approach will use radiopharmaceuticals for detection and diagnosis with the ability to incorporate combination therapies to interrupt the replication of the virus.
  • The company considers that the drug platform will represent a novel theranostic technology which will establish a precision medicine therapeutic intervention that will be inexpensive and lead to more accurate diagnosis, treatment and evaluation of viral infections.
  • Vyripharm believes that this approach may have the potential to be a dominant novel application tool for the early diagnosis, monitoring, evaluation and treatment of coronavirus.
  • Our company recognized that looking at existing drugs that treat related viral infections would provide a timely approach to developing an effective treatment.

Therapeutic Drug Monitoring (TDM) Technologies, Markets & Companies to 2028 - ResearchAndMarkets.com

Friday, March 20, 2020 - 10:21am

The "Therapeutic Drug Monitoring (TDM) Technologies, Markets & Companies to 2028" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Therapeutic Drug Monitoring (TDM) Technologies, Markets & Companies to 2028" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • This report deals with therapeutic drug monitoring, a multi-disciplinary clinical specialty, aimed at improving patient care by monitoring drug levels in the blood to individually adjust the dose of drugs for improving outcome.
  • TDM is viewed as a component of personalized medicine that interacts with several other disciplines including pharmacokinetics and pharmacogenetics.
  • The report contains profiles of 35 companies involved in developing tests and equipment for drug monitoring along with their collaborations.

Therapeutic Drug Monitoring (TDM) and Drugs of Abuse (DoA) Study, 2018 to 2028 - Technologies, Applications, Markets, 35 Company Profiles

Monday, March 16, 2020 - 2:30pm

DUBLIN, March 16, 2020 /PRNewswire/ -- The "Therapeutic Drug Monitoring (TDM) Technologies, Markets & Companies to 2028" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 16, 2020 /PRNewswire/ -- The "Therapeutic Drug Monitoring (TDM) Technologies, Markets & Companies to 2028" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • This report deals with therapeutic drug monitoring, a multi-disciplinary clinical specialty, aimed at improving patient care by monitoring drug levels in the blood to individually adjust the dose of drugs for improving outcome.
  • TDM is viewed as a component of personalized medicine that interacts with several other disciplines including pharmacokinetics and pharmacogenetics.
  • The report contains profiles of 35 companies involved in developing tests and equipment for drug monitoring along with their collaborations.

Global Genomics Market (2020 to 2027) - Key Players Include Thermo Fisher Scientific, Life Technologies & Affymetrix Among Others - ResearchAndMarkets.com

Monday, March 16, 2020 - 3:30pm

The global genomics market size is expected to reach USD 31.1 billion by 2027, registering a CAGR of 7.7% over the forecast period according to this report.

Key Points: 
  • The global genomics market size is expected to reach USD 31.1 billion by 2027, registering a CAGR of 7.7% over the forecast period according to this report.
  • Significant changes in disease management processes along with advancements in genomics and personalized medicine are expected to propel the market.
  • Increasing pool of market innovators such as 23andMe, Oxford Nanopore Technologies, and Veritas Genetics that have launched breakthrough genomic technologies in recent years are also contributing toward market development.
  • 23andMe has expertise in developing direct-to-consumer genomic tests targeted toward disease prognosis and has recently received FDA approval for its commercialization.

Italy In-Vitro Diagnostics Market to 2025 - Analysis, Drivers & Restraints - ResearchAndMarkets.com

Wednesday, March 11, 2020 - 2:30pm

The "Italy In-Vitro Diagnostics Market - Growth, Trends & Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Italy In-Vitro Diagnostics Market - Growth, Trends & Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
  • The rising prevalence of chronic disease in Italy has been the primary driver for the growth of this market.
  • Moreover, increasing awareness and acceptance of personalized medicine and companion diagnostics have also helped the market growth.
  • These increasing incidence of diabetes is thus expected to increase the demand for early diagnostics tests, which will help the growth of this market.

Global Precision Medicine Market was Estimated to Grow at a Rate of 20.9% During the Forecast Period due to Increasing Focus of Healthcare Sector on Delivering Customized Personal Care: Absolute Markets Insights

Wednesday, March 11, 2020 - 12:00pm

Sequencing or characterizing genes is therefore the most important method of gathering information on genes and their possible mutations.

Key Points: 
  • Sequencing or characterizing genes is therefore the most important method of gathering information on genes and their possible mutations.
  • Technological advances in big data analysis and the introduction of new technologies will have a positive impact on the growth of the precision medicine market.
  • Massive demand for such software will increase the growth of the precision medicine market in healthcare companies for better patient engagement.
  • The regional development will be driven by a favorable policy scenario coupled with increased support for precision medicine research.